Elicio Therapeutics (ELTX) Income Statement: Revenue & Earnings

Elicio Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Elicio Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	2.30	28.31	2.88
Cost of Revenue	1.18	0.00	0.00	0.43	1.19
Gross Profit	-1.18	0.00	2.30	27.88	1.69
Operating Expenses
Research & Development	33.66	23.85	18.10	17.93	12.72
Selling, General & Administrative	11.33	11.90	5.63	7.54	3.00
Operating Expenses	44.99	35.75	23.73	25.47	15.72
Operating Income	-44.99	-35.75	-23.73	-25.47	-15.72
Other Income/Expense
Interest Income	0.78	0.37	0.07	0.00	0.01
Interest Expense	0.46	1.06	-3.60	0.88	0.00
Other Income/Expense	-7.23	1.24	-0.95	-0.05	-15.99
Income
Income Before Tax	-51.90	-35.20	-28.21	-26.40	-15.71
Income Tax Expense	0.00	-10.86	-7.26	-5.46	0.00
Net Income	-51.90	-35.20	-28.21	-26.40	-15.71
Net Income - Continuous Operations	-51.90	-35.20	-28.21	-26.40	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-50.27	-32.97	-23.34	-25.27	-15.53
EBIT	-51.44	-34.14	-23.73	-25.52	-15.72
Depreciation & Amortization	1.18	1.17	0.39	0.25	0.19
Earnings Per Share
Basic EPS	-4.00	-7.00	-89.00	-3.00	-1.00
Diluted EPS	-4.00	-7.00	-89.00	-3.00	-1.00
Basic Shares Outstanding	12.20	5.06	0.32	10.46	10.73
Diluted Shares Outstanding	12.20	5.06	0.32	10.46	10.73